Literature DB >> 22972636

Predicting positivity for a new era of Alzheimer disease prevention trials.

Jeffrey M Burns, William E Klunk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22972636     DOI： 10.1212/WNL.0b013e31826e26db

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.

Authors:  Joshua D Grill; Yan Zhou; David Elashoff; Jason Karlawish
Journal:  Neurobiol Aging       Date:  2015-11-22       Impact factor: 4.673

2.  Practice effects and amyloid deposition: preliminary data on a method for enriching samples in clinical trials.

Authors:  Kevin Duff; Norman L Foster; John M Hoffman
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jul-Sep       Impact factor: 2.703

3.  Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.

Authors:  Kumar B Rajan; Robert S Wilson; Jennifer Weuve; Lisa L Barnes; Denis A Evans
Journal:  Neurology       Date:  2015-06-24       Impact factor: 9.910

4.  Should we disclose amyloid imaging results to cognitively normal individuals?

Authors:  Joshua D Grill; David K Johnson; Jeffrey M Burns
Journal:  Neurodegener Dis Manag       Date:  2013-02

5.  Short-Term Practice Effects and Amyloid Deposition: Providing Information Above and Beyond Baseline Cognition.

Authors:  K Duff; D B Hammers; B C A Dalley; K R Suhrie; T J Atkinson; K M Rasmussen; K P Horn; B E Beardmore; L D Burrell; N L Foster; J M Hoffman
Journal:  J Prev Alzheimers Dis       Date:  2017

6.  Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.

Authors:  Kristin Harkins; Pamela Sankar; Reisa Sperling; Joshua D Grill; Robert C Green; Keith A Johnson; Megan Healy; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2015-05-12       Impact factor: 6.982

7.  Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.

Authors:  Joshua D Grill; Chelsea G Cox; Kristin Harkins; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2018-12-22       Impact factor: 6.982

Review 8.  Study partners should be required in preclinical Alzheimer's disease trials.

Authors:  Joshua D Grill; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2017-12-06       Impact factor: 6.982

9.  Recruiting to preclinical Alzheimer's disease clinical trials through registries.

Authors:  Joshua D Grill
Journal:  Alzheimers Dement (N Y)       Date:  2017-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.